Human proof of concept

Most delivery technologies rest on a translational leap from preclinical models to people, and that leap is where a lot of them fail. We chose to start in people instead.

Delivery is unusually hard to predict from animals. How a carrier moves through skin, reaches solid tissue, or holds together in the body depends on details that differ from species to species. A carrier that looks perfect in a mouse can behave differently in a person, and by the time that shows up, years and a great deal of money have already been spent. The translation gap is not a minor footnote in delivery. It is often the whole story.

Start where the evidence is real

Rather than accumulate preclinical evidence and hope it carries over, we work first in the least-regulated human use cases that can answer the delivery question directly. That means we see the platform performing in human tissue early, on real people, before committing a program to it.

Why it changes the risk

Human proof of concept retires the single biggest question that sinks delivery technologies: will this actually work in a person. When that question is answered up front, everything downstream is de-risked. A partner is not betting on a model organism. An investor is not underwriting a translation leap. The evidence is already human.

Evidence that funds itself

Starting in accessible human use cases has a second benefit. Those uses generate revenue and human data at the same time, so the science advances without depending only on the next round of funding. The same evidence that de-risks the platform also helps pay for the work that comes next.

It is a different order of operations from conventional biotech, and a deliberate one. Prove it in people, then build on proof.